Skip to main content

Table 3 Isolates were tested against antibiotics by disc diffusion

From: Effects of a combination of amlodipine and imipenem on 42 clinical isolates of Acinetobacter baumannii obtained from a teaching hospital in Guangzhou, China

Isolate no.

SCF

TZP

CAZ

CRO

FEP

ATM

IPM

MEM

LEV

CIP

AK

DO

TGC

PB

TOB

Phenotype/MBL

1

R

R

R

R

R

R

R

R

R

R

R

R

S

S

R

XDR/Neg

2

R

R

R

R

R

R

R

R

R

R

R

R

S

S

R

XDR/Neg

3

R

R

R

R

R

R

R

R

R

R

R

R

S

S

R

XDR/Neg

4

R

R

R

R

R

R

R

R

R

R

R

R

I

S

R

XDR/Neg

5

R

R

R

R

R

R

R

R

R

R

R

R

I

S

R

XDR/Neg

6

R

R

R

R

R

R

R

R

R

R

S

R

I

S

S

MDR/Neg

7

R

R

R

R

R

R

R

R

R

R

R

R

I

S

R

XDR/Neg

8

R

R

R

R

R

R

R

R

R

R

R

R

I

S

R

XDR/Neg

9

R

R

R

R

R

R

R

R

R

R

R

R

I

S

R

XDR/Neg

10

R

R

R

R

R

R

R

R

R

R

R

R

I

S

R

XDR/Neg

11

R

R

R

R

R

R

R

R

R

R

R

R

I

S

R

XDR/Neg

12

R

R

R

R

R

R

R

R

R

R

S

R

I

S

S

MDR/Neg

13

R

R

R

R

R

R

R

R

R

R

R

R

I

S

R

XDR/Neg

14

S

R

R

R

R

R

I

I

R

R

R

R

S

S

R

MDR/Neg

15

R

R

R

R

R

R

R

R

R

R

R

R

I

S

R

XDR/Neg

16

R

R

R

R

R

R

R

R

R

R

R

R

R

S

R

XDR/Neg

17

R

R

R

R

R

R

R

R

R

R

R

R

I

S

R

XDR/Neg

18

R

R

R

R

R

R

R

R

R

R

R

R

I

S

R

XDR/Neg

19

R

R

R

R

R

R

R

R

R

R

R

R

I

S

R

XDR/Neg

20

I

R

R

R

R

R

R

R

R

R

R

I

S

S

R

XDR/Neg

21

R

R

R

R

R

R

R

R

R

R

R

R

R

S

R

XDR/Neg

22

R

R

R

R

R

R

R

R

R

R

S

R

R

S

S

MDR/Neg

23

I

R

R

R

R

R

R

R

R

R

R

R

S

S

R

XDR/Neg

24

S

R

R

R

R

R

S

S

R

R

S

R

I

S

S

MDR/Neg

25

R

R

R

R

R

R

R

R

R

R

R

R

S

S

R

XDR/Neg

26

R

R

R

R

R

R

R

R

R

R

R

R

S

S

R

XDR/Neg

27

R

R

R

R

R

R

S

I

R

R

R

R

I

S

R

MDR/Neg

28

I

R

R

R

R

R

R

R

R

R

R

R

S

S

R

XDR/Neg

29

I

R

R

R

R

R

R

R

R

R

R

I

S

S

R

XDR/Neg

30

R

R

R

R

R

R

R

R

R

R

R

R

I

S

R

XDR/Neg

31

R

R

R

R

R

R

R

R

R

R

R

R

I

S

R

XDR/Neg

32

I

R

R

R

I

R

S

S

R

R

R

I

I

S

R

MDR/Neg

33

R

R

R

R

R

R

R

R

R

R

R

R

I

S

R

XDR/Neg

34

R

R

R

R

R

R

R

R

R

R

R

R

I

S

R

XDR/Neg

35

R

R

R

R

R

R

R

R

R

R

R

R

I

S

R

XDR/Neg

36

I

R

R

R

R

I

R

R

R

R

R

S

S

S

R

MDR/Neg

37

R

R

R

R

R

R

R

R

R

R

R

R

I

S

R

XDR/Neg

38

R

R

R

R

R

R

R

R

R

R

R

R

I

S

R

XDR/Neg

39

R

R

R

R

R

R

R

R

R

R

R

I

S

S

R

XDR/Pos

40

R

R

R

R

R

R

R

R

R

R

R

R

I

S

R

XDR/Neg

41

I

R

R

R

R

R

S

I

R

R

R

R

R

S

R

MDR/Neg

42

I

S

R

R

R

R

S

S

I

R

R

I

R

S

R

MDR/Neg

Susceptible (%)

2.4

2.4

0.0

0.0

0.0

0.0

11.9

7.1

0.0

0.0

9.5

0.0

28.6

100.0

9.5

-

  1. Metallo-β-lactamase was detected by MBL Etest.
  2. R, resistance; S, sensitivity; I, intermediate; XDR, extensively drug-resistant; MDR, multidrug-resistant; MBL, metallo-β-lactamase; Pos, positive; Neg, negative; PB, polymyxin B (300 units); TGC, tigecycline (15 μg); IPM, imipenem (10 μg); AK, amikacin (30 μg); TOB, tobramycin (10 μg); MEM, meropenem (10 μg); TZP, piperacillin/tazobactam (100/10 μg); SCF, cefoperazone/sulbactam (70/35 μg); CAZ, ceftazidime (30 μg); CRO, ceftriaxone (30 μg); FEP, cefepime (30 μg); ATM, aztreonam (30 μg); LEV, levofloxacin (5 μg); CIP, ciprofloxacin (5 μg); DO, doxycycline (30 μg).